Mangostanaxanthones III and IV: advanced glycation end-product inhibitors from the pericarp of Garcinia mangostana

详细信息    查看全文

• 作者：Hossam M. Abdallah ; Hany M. El-Bassossy ; Gamal A. Mohamed…
• 关键词：Garcinia mangostana ; Mangostanaxanthone ; Clusiaceae ; Diabetes ; Glycation end ; products
• 刊名：Journal of Natural Medicines
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：71
• 期：1
• 页码：216-226
• 全文大小：
• 刊物主题：Pharmacology/Toxicology; Plant Sciences; Complementary & Alternative Medicine; Medicinal Chemistry; Pharmacy;
• 出版者：Springer Japan
• ISSN：1861-0293
• 卷排序：71

文摘

Advanced glycation end-products (AGEs) are associated with a non-enzymatic reaction between the amino group of a protein and the carbonyl group of a sugar during hyperglycemia. The precipitation of AGEs in different tissues leads to many complications, such as endothelial dysfunction, cardiovascular complications, atherosclerosis, retinopathy, neuropathy, and Alzheimer’s disease. Garcinia mangostana L. (Clusiaceae) (GM) was selected owing to the ability of its polar and non-polar fractions to inhibit AGE formation. For the first time, the bioguided fractionation of its pericarp MeOH extract (GMT) gave rise to two new xanthones, namely, mangostanaxanthones III (1) and IV (3), in addition to six known compounds, β-mangostin (2), garcinone E (4), rubraxanthone (5), α-mangostin (6), garcinone C (7), and 9-hydroxycalabaxanthone (8), from the non-polar faction. Their structures were verified by various spectroscopic methods, including 1D and 2D NMR studies and high-resolution MS data. All of the isolated xanthones significantly inhibited both sugar (ribose) and dicarbonyl compound (methylglyoxal)-induced protein glycation in a dose-dependent manner. This is explained by the ability of the isolated xanthones to inhibit protein oxidation, as indicated by the decreases in dityrosine and N′-formylkynurenine formation.